GBA Gene Therapy for Parkinson's Disease

GBA Gene Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GBA Gene Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Migalastat (Galafold)</td>
<td>Amicus</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Venglustat (GZ161)</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ambroxol-PD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">GBA-PD Natural History</td>
<td>Observational</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AADC</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Gene therapy/chaperone</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>ASO/siRNA</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">IGF1 Peptide</td>
<td>Research</td>
</tr>
<tr>
<td class="label">IGF1 Mimetics</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Receptor Agonists</td>
<td>Research</td>
</tr>
</table>

Introduction

Overview

...

GBA Gene Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GBA Gene Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Migalastat (Galafold)</td>
<td>Amicus</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Venglustat (GZ161)</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ambroxol-PD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">GBA-PD Natural History</td>
<td>Observational</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AADC</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Gene therapy/chaperone</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>ASO/siRNA</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">IGF1 Peptide</td>
<td>Research</td>
</tr>
<tr>
<td class="label">IGF1 Mimetics</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Receptor Agonists</td>
<td>Research</td>
</tr>
</table>

Introduction

Overview

GBA Gene Therapy is an emerging experimental approach for treating Parkinson's disease (PD) in patients with GBA mutations. The glucocerebrosidase (GCase) enzyme, encoded by the GBA gene, plays a critical role in lysosomal function, and mutations in GBA represent one of the most significant genetic risk factors for PD. [@sardi2011]

Background

GBA Mutations and Parkinson's Disease

• 10-15% of PD patients carry GBA mutations
• GBA mutations increase PD risk 5-6 fold in heterozygotes
• Associated with earlier onset and more severe cognitive symptoms
• GBA is the most common genetic risk factor for PD aside from LRRK2 and SNCA

The GCase-Lysosome Connection

The glucocerebrosidase enzyme (GCase) is responsible for breaking down glucosylcer lysamide inosomes. Loss of GCase function leads to: [@mazzulli2016]

Glucosylceramide accumulation in lysosomes

Lysosomal dysfunction and impaired [autophagy](/entities/autophagy)

[α-Synuclein](/proteins/alpha-synuclein) aggregation (GCase regulates SNCA clearance)

Mitochondrial dysfunction

Endoplasmic reticulum stress

Therapeutic Approaches

1. Enzyme Replacement Therapy (ERT)

• Recombinant GCase delivery to increase enzymatic activity
• Limitations: Cannot cross the blood-brain barrier
• Currently only approved for Gaucher disease, not PD

2. Gene Therapy Vectors

AAV Vectors

• AAV9 serotype preferentially targets [neurons](/entities/neurons)
• Delivers functional GBA1 gene
• Promoters: Synapsin (neuronal), [GFAP](/entities/gfap) (astrocytic)
• Clinical trials in planning stages

Lentiviral Vectors

• Used in preclinical studies
• Provides long-term expression
• Safety concerns about insertional mutagenesis

3. Small Molecule Chaperones

Pharmacological chaperones stabilize mutant GCase and promote proper folding: [@mullin2020]

4. Substrate Reduction Therapy

• Venglustat (GZ/SAR402671) reduces glucosylceramide substrate
• Aims to compensate for reduced GCase activity
• Clinical trials for PD with GBA mutations

5. Gene Editing (CRISPR/Cas9)

• In vivo gene editing approaches being developed
• Corrects GBA mutations in the brain
• Challenges: Delivery across blood-brain barrier
• Preclinical stages

Clinical Development

Ongoing Trials

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) - vectors must cross BBB

Delivery - targeting specific brain regions (substantia nigra)

Expression levels - balancing therapeutic vs. toxic overexpression

Immunogenicity - immune response to viral vectors

Patient selection - identifying GBA mutation carriers

Mechanism of Action

In Parkinson's Disease

Restore GCase activity in neurons and glia

Reduce glucosylceramide accumulation

Improve lysosomal function

Enhance α-synuclein clearance

Protect dopaminergic neurons

Downstream Effects

Preclinical Evidence

Animal Models

• Gba1 knockout mice: Show increased α-synuclein aggregation
• AAV-GBA delivery: Reduces α-synuclein in mouse models
• Combination therapy: GBA + SNCA knockdown shows synergy

Cell Models

• iPSC-derived neurons from GBA PD patients
• Gene therapy rescues lysosomal deficits
• Reduces pathological α-synuclein

Comparison to Other PD Gene Therapies

Future Directions

Promising Strategies

Brain-targeted AAV vectors - improved BBB crossing

Regulatable promoters - control expression levels

Combination approaches - GBA + α-synuclein targeting

Patient stratification - GBA mutation carriers only

Early intervention - prodromal PD patients

Key Questions

• Will gene therapy work in sporadic PD?
• What is the optimal delivery method?
• How long will therapeutic effects last?
• Can this prevent cognitive decline in GBA-PD?

Related Content

Related Diseases

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Dementia](/diseases/parkinson-disease-dementia)
• [Gaucher Disease](/diseases/gaucher-disease)
• [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)

Related Genes

• [GBA Gene](genes/gba)
• [GBA2 Gene](genes/gba2)
• [SNCA Gene](genes/snca)
• [LRRK2 Gene](genes/lrrk2)

Related Mechanisms

• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)

Related Treatments

• [Gene Therapy Overview](treatments/gene-therapy)
• [AAV Vectors](treatments/aav-vectors-neurodegenerative-gene-therapy)
• [LRRK2 Inhibitors](treatments/lrrk2-inhibitors)
• [Alpha-Synuclein Immunotherapy](treatments/alpha-synuclein-immunotherapy)

Key Publications

[Glucocerebrosidase and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25977245) - Reviews GBA-PD connection

[AAV-GBA gene therapy for PD](https://pubmed.ncbi.nlm.nih.gov/29867231) - Preclinical proof of concept

[Ambroxol for PD trial](https://pubmed.ncbi.nlm.nih.gov/33185066) - Phase II trial design

[Substrate reduction therapy in PD](https://pubmed.ncbi.nlm.nih.gov/28750070) - Venglustat development

See also: [Gene Therapy](treatments/gene-therapy), [AAV Vectors](treatments/aav-vectors-neurodegenerative-gene-therapy), [Parkinson's Disease](/diseases/parkinsons-disease)

See Also

• [Treatments Index](/therapeutics)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GBA Gene](/proteins/gba-protein)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

External Links

• [ClinicalTrials.gov: GBA Gene Therapy](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=GBA+gene+therapy)
• [NIH: GBA1 and Parkinson Disease](https://www.ninds.nih.gov/current-research/focus-areas/parkinsons-disease)
• [Michael J. Fox Foundation: GBA](https://www.michaeljfox.org/gba-parkinsons-research)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

2.彭斯 等. (2018). "AAV-GBA1 gene delivery in mouse models." Mol Ther 26(8):2052-2065. PMID: 29982369(https://pubmed.ncbi.nlm.nih.gov/29982369/).

[@ref2019]:

[@mazzulli]: Mazzulli JR, et al. "Small molecule GBA activators." Cell 166(6):1534-1545. PMID: 27594434(https://pubmed.ncbi.nlm.nih.gov/27594434/).

[@schondorf]: Schondorf DC, et al. "iPSC models of GBA1-associated Parkinson's disease." Nat Commun 9(1):2904. PMID: 30013145(https://pubmed.ncbi.nlm.nih.gov/30013145/).

IGF1 in Neurodegeneration

Alzheimer's Disease

• IGF1 signaling plays a complex role in AD pathophysiology
• Both beneficial (neuroprotection) and detrimental (Aβ production) effects
• Brain IGF1 resistance observed in AD patients
• Therapeutic potential of IGF1 modulators under investigation

Parkinson's Disease

• IGF1 provides neuroprotection to dopaminergic neurons
• Motor performance improvements in PD models with IGF1 treatment
• Interaction with dopamine signaling pathways

ALS

• IGF1 promotes motor neuron survival
• Delivery challenges due to blood-brain barrier
• Gene therapy approaches being explored

Therapeutic Approaches

Research Directions

Current research focuses on:

• Understanding tissue-specific IGF1 signaling
• Developing brain-penetrant IGF1 analogs
• Combination therapies targeting multiple pathways
• Biomarkers for IGF1 response monitoring

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;